BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3778510)

  • 1. Subcellular and extracellular localization of specific binding sites for triphenylethylene antiestrogens in human breast cancer.
    Gulino A; Vacca A; Modesti A; Screpanti I; Farina A; Frati L
    Biochem Pharmacol; 1986 Nov; 35(21):3863-70. PubMed ID: 3778510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK; Sutherland RL
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
    Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.
    Watts CK; Sutherland RL
    Biochem J; 1986 Jun; 236(3):903-11. PubMed ID: 3790095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
    Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
    Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
    Burke PJ; Kalet BT; Koch TH
    J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
    Sheen YY; Simpson DM; Katzenellenbogen BS
    Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of the microsomal tamoxifen binding site.
    Kedjouar B; de Médina P; Oulad-Abdelghani M; Payré B; Silvente-Poirot S; Favre G; Faye JC; Poirot M
    J Biol Chem; 2004 Aug; 279(32):34048-61. PubMed ID: 15175332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogen binding sites in microsomal fractions of malignant and nonmalignant human breast tissues.
    Mehta RR; DasGupta TK
    Breast Cancer Res Treat; 1987; 9(1):61-7. PubMed ID: 3593991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver.
    Winneker RC; Clark JH
    Endocrinology; 1983 Jun; 112(6):1910-5. PubMed ID: 6682755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen inhibition of prolactin action in the mouse mammary gland.
    Biswas R; Vonderhaar BK
    Endocrinology; 1991 Jan; 128(1):532-8. PubMed ID: 1846110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiestrogen binding sites in brain and pituitary of ovariectomized rats.
    Gray JM; Ziemian L
    Brain Res; 1992 Apr; 578(1-2):55-60. PubMed ID: 1511289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
    Lyman SD; Jordan VC
    Biochem Pharmacol; 1985 Aug; 34(15):2795-806. PubMed ID: 4015716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of tamoxifen in the chicken.
    Lazier CB
    J Steroid Biochem; 1987; 27(4-6):877-82. PubMed ID: 3320566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and antiestrogen binding sites in desmoid tumors.
    Lim CL; Walker MJ; Mehta RR; Das Gupta TK
    Eur J Cancer Clin Oncol; 1986 May; 22(5):583-7. PubMed ID: 3770030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of an antiestrogen-binding protein in high salt extracts of human breast cancer tissue.
    Kon OL
    J Steroid Biochem; 1985 Feb; 22(2):177-86. PubMed ID: 3982029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of estrogen and antiestrogen binding to the cytosol and microsomes of breast tumors.
    Lopes MC; Tavares MC; Vale MG; Carvalho AP
    J Steroid Biochem Mol Biol; 1991 Sep; 39(3):343-52. PubMed ID: 1911424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogen binding within different pituitary cell populations. Comparison with androgen and estrogen receptors.
    Thieulant ML; Adelaide J; Duval J
    J Steroid Biochem; 1986 Jan; 24(1):395-9. PubMed ID: 3702423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.
    Payré B; de Medina P; Boubekeur N; Mhamdi L; Bertrand-Michel J; Tercé F; Fourquaux I; Goudounèche D; Record M; Poirot M; Silvente-Poirot S
    Mol Cancer Ther; 2008 Dec; 7(12):3707-18. PubMed ID: 19074846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.